Matthew Moss, MD
Urology · Jackson, MSNPI 1710418546
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 193 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 19.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,259, 2.7 times the $467 reported in 2019.
Across 193 payments — averaging $29.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- Boston Scientific$989
- Dendreon Pharmaceuticals LLC$689
- Urogen Pharma, Inc.$346
- Myriad Genetic Laboratories, Inc.$287
- Bayer$283
- plus $2K from 28 others
What the payments were for
- Food & beverage$5,66099%
- Education$541%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 59 | $1,088 |
| Boston Scientific | 11 | $989 |
| Dendreon Pharmaceuticals LLC | 18 | $689 |
| Urogen Pharma, Inc. | 6 | $346 |
| Myriad Genetic Laboratories, Inc. | 4 | $287 |
| Bayer | 15 | $283 |
| Sumitomo Pharma America, Inc. | 11 | $244 |
| Baxter Healthcare | 2 | $238 |
| Pfizer | 12 | $224 |
| AbbVie | 9 | $173 |
| Astellas Pharma US Inc | 7 | $135 |
| Teleflex LLC | 2 | $119 |
| Tolmar, Inc. | 6 | $112 |
| Cook Medical LLC | 1 | $93 |
| Axonics, Inc. | 1 | $85 |
| Accord Healthcare, Inc. | 4 | $68 |
| Coloplast | 1 | $68 |
| Olympus America Inc. | 3 | $65 |
| Verity Pharmaceuticals Inc. | 3 | $51 |
| Merck | 3 | $46 |
| Axogen | 1 | $43 |
| Progenics Pharmaceuticals, Inc. | 2 | $40 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $30 |
| 180 Medical, Inc. | 1 | $24 |
| Procept Biorobotics Corporation | 1 | $22 |
| Novartis | 1 | $21 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| Caris MPI, Inc. | 1 | $18 |
| Medtronic | 1 | $17 |
| ABC Home Medical Supply, Inc. | 1 | $17 |
| Ferring Pharmaceuticals Inc. | 1 | $16 |
| Mission Pharmacal Company | 1 | $16 |
| Civco Medical Instruments | 1 | $15 |
| Amgen | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,714 in reported general payments places this provider in the 65th percentile of 94 urology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 51 | $705,387 |
| XtandiEnzalutamide | 49 | $658,626 |
| TrelstarTriptorelin Pamoate | 44 | $204,968 |
| Abiraterone Acetate | 14 | $48,657 |
| GemtesaVibegron | 39 | $21,966 |
| MyrbetriqMirabegron | 39 | $19,195 |
| Tamsulosin Hcl | 826 | $11,603 |
| Finasteride | 306 | $4,561 |
| Dutasteride | 95 | $4,021 |
| Bicalutamide | 82 | $2,360 |
| NitrofurantoinNitrofurantoin Macrocrystal | 29 | $1,086 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 75 | $915 |
| Estradiol | 13 | $903 |
| Tolterodine Tartrate ErTolterodine Tartrate | 15 | $740 |
| Potassium Citrate ErPotassium Citrate | 12 | $710 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada | $1,088 | $705,38751 claims |
| Astellas Pharma US IncXtandi, Myrbetriq | $135 | $677,82188 claims |
| Verity Pharmaceuticals Inc.Trelstar | $51 | $204,96844 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $244 | $21,96639 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 94 urology providers in Mississippi.
Other urology in Jackson
- Harold BlalockJackson$15K
- Patrick DailyJackson$12K
- Mark RunnelsJackson$10K
- Allen HarawayJackson$8K
- John AdamsJackson$8K
- Michael WoodJackson$8K
- Chadwick HuckabayJackson$8K
- Ronald DavisJackson$6K
- Felix Gordon JrJackson$6K
- Kieran HynesJackson$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.